Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase IIIb trial L. Ladrón-de-Guevara, L. Bornstein-Quevedo, S. González-Huezo, B. Castañeda-Romero, F.G. Costa, M. di Silvio-López

Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMG L.R. Valdovinos-García, A.S. Villar-Chávez, F.M Huerta-Iga, M. Amieva-Balmori, J.S. Arenas-Martínez, R. Bernal-Reyes, E. Coss-Adame, O. Gómez-Escudero, P.C. Gómez-Castaños, M. González-Martínez, E.C Morel-Cerda, J.M. Remes-Troche, M.C. Rodríguez-Leal, D. Ruiz-Romero, M.A. Valdovinos-Diaz, G. Vázquez-Elizondo, J.A. Velarde-Ruiz Velasco, M.R. Zavala-Solares

Systematic review: Effect of proton pump inhibitors on Helicobacter pylori physiology V. Blandón-Arias, A.M. Ospina-Gil, B.E. Salazar-Giraldo, T.L. Pérez-Cala